Pulmonary hemodynamics at baseline and targeted pulmonary arterial hypertension (PAH) therapy in twenty-two patients with PAH undergoing oscillatory whole-body vibration (WBV) in the “WBV only” and “Control-WBV” (initial control, subsequent WBV) groups
| WBV only (n=11) | Control-WBV (n=11) | All (n=22) | |
|---|---|---|---|
| Hemodynamics | |||
| PAP systolic (mm Hg) | 58.5±8.4 | 64.5±5.5 | 61.5±4.9 |
| PAP diastolic (mm Hg) | 20.7±2.6 | 25.6±3.1 | 23.2±2.1 |
| PAP mean (mm Hg) | 35.5±4.2 | 41.9±3.6 | 38.7±2.8 |
| PAWP (mm Hg) | 11.1±1.1 | 9.3±1.1 | 10.2±0.8 |
| TPG (mm Hg) | 24.7±4.6 | 33.2±3.3 | 28.9±2.9 |
| DPG (mm Hg) | 9.6±3.0 | 16.4±2.8 | 13.0±2.1 |
| Cardiac output (L/min) | 4.3±0.2 | 4.6±0.3 | 4.5±0.2 |
| Cardiac index (L/min/m2) | 2.4±0.1 | 2.5±0.1 | 2.4±0.1 |
| PVR (WU) | 5.8±0.9 | 7.6±1.1 | 6.7±0.7 |
| Targeted PAH therapy | |||
| PDE5i monotherapy (n,%) | 6 (55) | 1 (9) | 7 (32) |
| ERA+PDE5i (n, %) | 2 (18) | 5 (46) | 7 (32) |
| ERA+sGC-S (n,%) | 1 (9) | 2 (18) | 3 (14) |
| ERA+PDE5i+PCA (n,%) | 1 (9) | 2 (18) | 3 (14) |
| PDE5i+TKI (n, %) | 0 | 1 (9) | 1 (4) |
| ERA+PDE5i+TKI (n, %) | 1 (9) | 0 | 1 (4) |
Values represent numbers of patients (n, %) or mean values±SEM.
DPG, diastolic pressure gradient (=PAPdiast – PAWP); ERA, Endothelin receptor antagonist; PAP, Pulmonary artery pressure; PAWP, Pulmonary arterial wedge pressure; PCA, Prostanoid; PDE5i, Phosphodiesterase type 5 inhibitor; PVR, Pulmonary vascular resistance (=TPG/CO); SEM, standard error of the mean; sGC-S, soluble guanylate cyclase stimulator; TKI, Tyrosine kinase inhibitor; TPG, transpulmonary pressure gradient (=PAPmean—PAWP).